Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy oleh Shivshankari Rajkumar, Diana Berry, Kayla A. Heney, Colton Strong, LeeAnn Ramsay, Mathieu Lajoie, Rached Alkallas, Tan-Trieu Nguyen, Cameron Thomson, Mozhdeh Ahanfeshar-Adams, Matthew Dankner, Teresa Petrella, April A.N. Rose, Peter M. Siegel, Ian R. Watson